Merrimack commences patient enrollment in MM-141 Phase 1 study

MM-141, the company’s sixth oncology candidate that advanced into clinical development, is developed to target P13K/AKT/mTOR pathway that is believed to play a vital role in tumor cell survival promotion.

Merrimack co-founder and chief scientific officer Ulrik Nielsen said, "Merrimack has engineered MM-141 to focus specifically on key pathways of IGF-1R and ErbB3 signaling to address this issue."

Study is designed to evaluate the safety profile of the investigational candidate as a monotherapy and combination therapy along with everolimus and docetaxel.

Trial expected to be conducted across four sites will also identify the recommended Phase 2 dose.